- Conditions
- Schizophrenia
- Interventions
- Xanomeline/Trospium Chloride, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 34
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- Xanomeline/trospium chloride
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Schizophrenia
- Interventions
- xanomeline-trospium chloride, Oral antipsychotics
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Suwanee, Georgia
- Conditions
- Schizophrenia
- Interventions
- KarXT (xanomeline and trospium)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
- Interventions
- Cobenfy KarXT pill (50/20 mg), Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
- Interventions
- Xanomeline and trospium chloride (KarXT)
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
- Interventions
- COBENFY KarXT (50/20 mg), Control
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy Volunteers
- Interventions
- Xanomeline/ Trospium Chloride
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Anaheim, California • Lenexa, Kansas • San Antonio, Texas
- Conditions
- Healthy Volunteers
- Interventions
- KarXT, Midazolam, Fexofenadine, Digoxin
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Cocaine Use Disorder (CUD)
- Interventions
- Cobenfy, Placebo
- Drug
- Lead sponsor
- Joshua A. Lile, Ph.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Schizophrenia
- Interventions
- Xanomeline/Trospium
- Drug
- Lead sponsor
- Vanguard Research Group
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Texas
- Conditions
- Schizophrenia
- Interventions
- KarXT
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 29
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more